CN102905688B - 用于前房内药物递送的缓释储库式植入物 - Google Patents

用于前房内药物递送的缓释储库式植入物 Download PDF

Info

Publication number
CN102905688B
CN102905688B CN201180023027.7A CN201180023027A CN102905688B CN 102905688 B CN102905688 B CN 102905688B CN 201180023027 A CN201180023027 A CN 201180023027A CN 102905688 B CN102905688 B CN 102905688B
Authority
CN
China
Prior art keywords
implant
drug
tube
core
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180023027.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102905688A (zh
Inventor
R·史
P·M·休斯
J·A·伯克
M·R·罗宾逊
刘辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN102905688A publication Critical patent/CN102905688A/zh
Application granted granted Critical
Publication of CN102905688B publication Critical patent/CN102905688B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180023027.7A 2010-04-06 2011-04-05 用于前房内药物递送的缓释储库式植入物 Expired - Fee Related CN102905688B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32142210P 2010-04-06 2010-04-06
US61/321,422 2010-04-06
PCT/US2011/031265 WO2011127064A2 (en) 2010-04-06 2011-04-05 Sustained-release reservoir implants for intracameral drug delivery

Publications (2)

Publication Number Publication Date
CN102905688A CN102905688A (zh) 2013-01-30
CN102905688B true CN102905688B (zh) 2015-11-25

Family

ID=44065364

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180023027.7A Expired - Fee Related CN102905688B (zh) 2010-04-06 2011-04-05 用于前房内药物递送的缓释储库式植入物

Country Status (10)

Country Link
US (3) US20130017243A1 (cg-RX-API-DMAC7.html)
EP (1) EP2555749B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013523821A (cg-RX-API-DMAC7.html)
KR (1) KR20130086131A (cg-RX-API-DMAC7.html)
CN (1) CN102905688B (cg-RX-API-DMAC7.html)
AU (1) AU2011237788A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012025581A2 (cg-RX-API-DMAC7.html)
CA (1) CA2795706A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012146630A (cg-RX-API-DMAC7.html)
WO (1) WO2011127064A2 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションDose Medical Corporation 薬剤溶出眼内インプラント
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
JP2013526572A (ja) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
EP3494959A3 (en) 2011-04-29 2019-09-11 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2014120866A1 (en) 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
EP2956096A1 (en) * 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
ES2751681T3 (es) * 2013-03-15 2020-04-01 Allergan Inc Implante intraocular que contiene prostamida
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
AU2014350095B9 (en) * 2013-11-14 2019-09-12 Eyed Pharma Eye device
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
BR112017007942A2 (pt) * 2014-10-30 2017-12-19 Textile Based Delivery Inc sistemas de liberação
CN104587850A (zh) * 2015-01-11 2015-05-06 王丽莉 一种聚偏氟乙烯中空纤维膜的制备方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
RU2620249C1 (ru) * 2015-12-17 2017-05-23 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Многослойный биодеградируемый глазной имплантат с дозированным высвобождением лекарственного вещества и способ его изготовления
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102814241B1 (ko) 2016-09-23 2025-05-29 인셉트, 엘엘씨 전안방내 약물 전달 데포
EP3518844A4 (en) * 2016-09-30 2020-05-27 Lynthera Corporation HIGH PRECISION DRUG DELIVERY THROUGH A DUAL DOMAIN EYE DEVICE
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11406533B2 (en) 2017-03-17 2022-08-09 W. L. Gore & Associates, Inc. Integrated aqueous shunt for glaucoma treatment
JP7770768B6 (ja) * 2017-10-13 2025-12-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 繊毛病に関連する疾患の治療方法
RU185437U1 (ru) * 2018-04-12 2018-12-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" Устройство для герметизации капсул алюминиевых
EP3793537A1 (en) * 2018-05-16 2021-03-24 Spirox, Inc. Allergic rhinitis drug delivery implant
EP3843676A1 (en) 2018-08-29 2021-07-07 W.L. Gore & Associates, Inc. Drug therapy delivery systems and methods
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11975087B2 (en) * 2020-03-30 2024-05-07 Colgate-Palmolive Company Sulfate-free personal care compositions and methods for preventing and treating pollution damage to skin
EP4021389A1 (en) 2020-03-30 2022-07-06 Colgate-Palmolive Company Personal care compositions
WO2021247690A1 (en) * 2020-06-03 2021-12-09 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use
US20230338278A1 (en) * 2020-09-17 2023-10-26 The University Of North Carolina At Chapel Hill Methods, Systems and Devices for Post-Fabrication Drug Loading
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US12527691B2 (en) 2021-11-05 2026-01-20 W. L. Gore & Associates, Inc. Fluid drainage devices, systems, and methods
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
TR200201047T2 (tr) * 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
BR0309844A (pt) * 2002-05-07 2005-02-15 Control Delivery Sys Inc Processos para formação de um dispositivo para a distribuição de droga
MXPA05007719A (es) * 2003-01-24 2005-09-30 Control Delivery Sys Inc Dispositivo de liberacion sostenida y metodo para la administracion ocular de agentes adrenergicos.
BRPI0406858A (pt) * 2003-01-24 2006-01-03 Control Delivery Sys Inc Liberação controlada de agentes altamente solúveis
PL1696822T3 (pl) * 2003-11-13 2010-08-31 Psivida Inc Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
CA2624174A1 (en) * 2005-09-28 2007-04-05 The Trustees Of The University Of Pennsylvania Self-assembled biodegradable polymersomes
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20080299176A1 (en) * 2007-05-30 2008-12-04 Yu-Chin Lai Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
US20120245505A1 (en) * 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery

Also Published As

Publication number Publication date
JP2015166361A (ja) 2015-09-24
KR20130086131A (ko) 2013-07-31
AU2011237788A1 (en) 2012-11-01
CA2795706A1 (en) 2011-10-13
WO2011127064A2 (en) 2011-10-13
US20160256382A1 (en) 2016-09-08
JP2013523821A (ja) 2013-06-17
US20130017243A1 (en) 2013-01-17
EP2555749A2 (en) 2013-02-13
BR112012025581A2 (pt) 2019-09-24
WO2011127064A3 (en) 2012-10-26
CN102905688A (zh) 2013-01-30
US20150104491A1 (en) 2015-04-16
EP2555749B1 (en) 2016-10-26
RU2012146630A (ru) 2014-05-20

Similar Documents

Publication Publication Date Title
EP2555749B1 (en) Sustained-release reservoir implants for intracameral drug delivery
US9669039B2 (en) Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US10064872B2 (en) Oil-in-water method for making polymeric implants containing a hypotensive lipid
DK2525776T3 (en) Intracameral implants WITH depot preparation
JP5826872B2 (ja) 眼内使用のための環状脂質インプラントの製造法
US8753666B2 (en) Punctal plugs and methods of delivering therapeutic agents
JP7278223B2 (ja) 生体浸食性薬物送達デバイス
US20060182781A1 (en) Methods for treating ocular conditions with cyclic lipid contraining microparticles
TW201012469A (en) Combination treatment of glaucoma
EP1944032A2 (en) Biodegradable intraocular implants containing prostamides
JP2006516618A (ja) アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法
HK1181641A (en) Sustained-release reservoir implants for intracameral drug delivery
HK40104453A (en) Bioerodible drug delivery devices
HK40020691B (en) Bioerodible drug delivery devices

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181641

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20160405

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1181641

Country of ref document: HK